thalidomide has been researched along with Neurofibroma, Plexiform in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Neurofibroma, Plexiform: A type of neurofibroma manifesting as a diffuse overgrowth of subcutaneous tissue, usually involving the face, scalp, neck, and chest but occasionally occurring in the abdomen or pelvis. The tumors tend to progress, and may extend along nerve roots to eventually involve the spinal roots and spinal cord. This process is almost always a manifestation of NEUROFIBROMATOSIS 1. (From Adams et al., Principles of Neurology, 6th ed, p1016; J Pediatr 1997 Nov;131(5):678-82)
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)." | 9.10 | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003) |
| "An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF)." | 5.10 | Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. ( Cohen, BH; Gupta, A; Packer, RJ; Phillips, PC; Ruggieri, P, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gupta, A | 1 |
| Cohen, BH | 1 |
| Ruggieri, P | 1 |
| Packer, RJ | 1 |
| Phillips, PC | 1 |
| Calligaris, L | 1 |
| Marchetti, F | 1 |
| Ventura, A | 1 |
1 trial available for thalidomide and Neurofibroma, Plexiform
| Article | Year |
|---|---|
Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Child; Cohort Studies; Dermatologic Agents; Dose-Respons | 2003 |
1 other study available for thalidomide and Neurofibroma, Plexiform
| Article | Year |
|---|---|
Intestinal plexiform neurofibromas.
Topics: Angiogenesis Inhibitors; Child; Diagnosis, Differential; Female; Humans; Ileal Neoplasms; Mesentery; | 2008 |